Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Trial Profile

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Doxorubicin (Primary) ; Lurbinectedin (Primary) ; Cyclophosphamide; Topotecan; Vincristine
  • Indications Bronchial cancer; Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLANTIS
  • Sponsors PharmaMar
  • Most Recent Events

    • 20 Feb 2018 According to a PharmaMar media release, the design of this trial will be presented at the International Association for the Study of Lung Cancer (IASLC) annual meeting. This study has already recruited more than two thirds of patients in more than 154 centers involved across 20 countries.
    • 15 Nov 2017 According to a PharmaMar media release, based on the analysis of the safety data of the first 150 patients, the Independent Data Monitoring Committee (IDMC) recommended to continue this trial without any changes.
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top